EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence and Clinical Significance of Potential Drug–Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study

Omid Reza Zekavat, Narjes Zarsanj, Adel Sadeghdoust iD, Alekhya Lavu, Mohammadreza Bordbar, Sherif Eltonsy iD, Payam Peymani iD

Cancers · 18.09.2025 · 17 (18) · 3054

DOI: 10.3390/cancers17183054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 18.09.2025. Verfasst von Omid Reza Zekavat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Research Centre, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz 71937-11351, Iran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug–drug interactions (DDIs) are frequent and potentially harmful in pediatric cancer patients due to polypharmacy and complex chemotherapy regimens. However, data on DDIs in hospitalized pediatric oncology patients remain limited, particularly in Middle Eastern settings.

Methods

In this prospective study, we analyzed prescriptions for hospitalized pediatric oncology patients in Iran to assess the prevalence, severity, and nature of potential DDIs (PDDIs). Chemotherapy and supportive medications were analyzed using two validated databases (Lexi-Interact™ and Drugs.com™) between November 2019 and June 2020.

Results

Of 80 patients (median age 8.9 years), 21.2% had at least one documented PDDI. We identified 197 total PDDIs involving 42 unique drug pairs. The most common DDIs included acetaminophen and granisetron (severity rating: moderate). Methotrexate and vincristine were the most frequent antineoplastic DDI pair. Methotrexate alone accounted for 156 interactions.

Conclusions

This is the first prospective study from Iran—and the largest in the region—investigating PDDIs in pediatric oncology. The dual-database screening approach improved PDDI detection. Clinical teams should routinely evaluate medication profiles in pediatric cancer patients to minimize avoidable harms from DDIs.

Schlagwörter

Stichwörter der Autor:innen

chemotherapydrug-drug interactionspediatric oncologypharmacoepidemiologysafety

Autor:innen und Institutionen

  • Hematology Research Centre, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz 71937-11351, Iran.
  • Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz 71348-45794, Iran.
  • College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.

ORCID-Profile: Adel Sadeghdoust, Sherif Eltonsy, Payam Peymani

Zitieren

APA

Zekavat, O. R., Zarsanj, N., Sadeghdoust, A., Lavu, A., Bordbar, M., Eltonsy, S., & Peymani, P. (2025). Prevalence and Clinical Significance of Potential Drug–Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study. Cancers, 17(18), 3054. https://doi.org/10.3390/cancers17183054

Vancouver

Zekavat OR, Zarsanj N, Sadeghdoust A, Lavu A, Bordbar M, Eltonsy S, et al. Prevalence and Clinical Significance of Potential Drug–Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study. Cancers. 2025;17(18):3054. doi:10.3390/cancers17183054

BibTeX
@article{Zekavat2025,
  author = {Zekavat, Omid Reza and Zarsanj, Narjes and Sadeghdoust, Adel and Lavu, Alekhya and Bordbar, Mohammadreza and Eltonsy, Sherif and Peymani, Payam},
  title = {Prevalence and Clinical Significance of Potential Drug–Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {18},
  pages = {3054},
  doi = {10.3390/cancers17183054}
}
Kostenlos starten →